EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hypoxia-induced tumor cell-intrinsic PLAU activation drives immunotherapy resistance in collagenic lung adenocarcinoma

Li Wan, Tianyun Ma, Boye Li, Xiaoming Shi, Shuwen Chen, Xiaoli Sun, Haotian Ge, Chuqiao Lu, Weiyong Yu, Ning Zhou, Yue Xu, Li Ma und 1 weitere

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Li Wan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China; Department of Oncology, The Affiliated…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Graduate Research and Innovation Projects of Jiangsu Province, National Natural Science Foundation of China, Jiangsu Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hypoxia, as one of the hallmarks in the progression of solid tumors, has been established as critically important for tumor adaptive survival; however, its role in mediating tumor microenvironment remodeling in advanced lung adenocarcinoma (LUAD) remains incompletely defined. METHODS: Bioinformatics methods were conducted to establish a "hypoxia gene module" and perform molecular subtyping of advanced LUAD patients.Western blotting and immunohistochemistry analyses were performed to elucidate the role of PLAU-PLAUR (also known as uPA-uPAR) signaling activation in hypoxia-associated "Collagenic" LUAD development. Primary pulmonary fibroblasts were isolated, and a co-culture system was established for further investigation. QRT-PCR, Western blotting, and ELISA assays were employed to assess PLAU-PLAUR pathway involvement in CAFs activation. Additionally, CUT&RUN, mass spectrometry, immunofluorescence, and co-immunoprecipitation experiments were conducted to explore the molecular mechanisms of HIF1A-induced PLAU upregulation. In vivo studies were undertaken to examine PLAU-PLAUR activation's impact on the formation of a collagen-rich tumor microenvironment. RESULTS: We observed that advanced LUAD patients with high hypoxia exhibited higher fibrosis and increased infiltration of immunosuppressive cells in their microenvironment. Screening intercellular communication signals revealed abnormal activation of the PLAU-PLAUR pathway between tumor cells and fibroblasts in hypoxia-induced "Collagenic" LUAD. In vitro experiments confirmed that hypoxia upregulates PLAU in tumor cells, promoting CAFs activation. Furthermore, hypoxia-inducible factor 1α(HIF1A) recruits the mitophagy protein NIX for a non-canonical role: under hypoxia, NIX translocates to the nucleus, interacts with the PLAU transcription factor YY1, and enhances its binding to the PLAU promoter. We also identified that PLAU activates Hippo-YAP signaling upon binding to PLAUR on lung fibroblasts. In vitro studies demonstrated that Upamostat significantly attenuated fibroblast activation at tumor borders, enhanced CD8+T cell infiltration, and shifted macrophages from immunosuppressive to immunogenic states. CONCLUSIONS: Activation of the PLAU-PLAUR pathway is essential for the progression of hypoxia-associated LUAD exhibiting a collagenous phenotype. Blocking the pathway provides a new research perspective for the development of immunotherapy for LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsHumansTumor MicroenvironmentAnimalsMiceCancer-Associated FibroblastsImmunotherapyCell Line, TumorSignal TransductionHypoxia-Inducible Factor 1, alpha SubunitFemaleDrug Resistance, NeoplasmMaleCell Hypoxia

Stichwörter der Autor:innen

Cancer-associated fibroblastsHypoxiaLung adenocarcinomaPLAU-PLAUR,Immunotherapy resistance

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitHIF1A protein, human

Autor:innen und Institutionen

  • Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China; Department of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian,…
  • Department of Oncology, Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an), Huaian, Jiangsu, China.
  • School of Mathematics and Statistics, Taishan University, Shandong,China.
  • Department of Thoracic Surgery, Affiliated Drum Tower Hospital, Nanjing University Medical College, Nanjing, Jiangsu, China; Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu,…
  • Department of Clinical Medicine, The First Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, Jiangsu, China.

Förderung

  • Graduate Research and Innovation Projects of Jiangsu Province
  • National Natural Science Foundation of China
  • Jiangsu Provincial Health Commission
  • Nanjing Medical University

Zitieren

APA

Wan, L., Ma, T., Li, B., Shi, X., Chen, S., Sun, X., Ge, H., Lu, C., Yu, W., Zhou, N., Xu, Y., Ma, L., & Wang, Z. (2025). Hypoxia-induced tumor cell-intrinsic PLAU activation drives immunotherapy resistance in collagenic lung adenocarcinoma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115161

Vancouver

Wan L, Ma T, Li B, Shi X, Chen S, Sun X, et al. Hypoxia-induced tumor cell-intrinsic PLAU activation drives immunotherapy resistance in collagenic lung adenocarcinoma. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115161

BibTeX
@article{Wan2025,
  author = {Wan, Li and Ma, Tianyun and Li, Boye and Shi, Xiaoming and Chen, Shuwen and Sun, Xiaoli and Ge, Haotian and Lu, Chuqiao and Yu, Weiyong and Zhou, Ning and Xu, Yue and Ma, Li and Wang, Zhaoxia},
  title = {Hypoxia-induced tumor cell-intrinsic PLAU activation drives immunotherapy resistance in collagenic lung adenocarcinoma},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115161}
}
Kostenlos starten →